Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Lymphoma Stories

2014-04-13 23:01:08

Transparency Market Research Report Added "Blood Disease Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" to its database. Browse Full Report: http://www.transparencymarketresearch.com/blood-disease-treatment-drugs.html. Albany, New York, USA (PRWEB) April 13, 2014 Blood comprises of red blood cells, white blood cells, plasma and platelets. Sometimes, people might be affected with different types of blood disorders and...

2014-04-10 12:24:44

Emerging Therapies are Not Expected to Offer Improvements in Safety and Tolerability Attributes, According to Findings from Decision Resources Group BURLINGTON, Mass., April 10, 2014 /PRNewswire/ -- Decision Resources Group finds that the effect of a therapy on overall survival and progression-free survival are attributes that most influence surveyed U.S. and European hematological oncologists' prescribing decisions for relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic...

2014-04-08 12:31:36

Community Leaders throughout the North Bay Area Assemble to Join LLS in the Fight against Blood Cancers SANTA ROSA, Calif., April 8, 2014 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society's (LLS) Greater Bay Area Chapter is launching its 2014 North Bay Man & Woman of the Year (MWOY) fundraising campaign, enlisting influential and compassionate community leaders as candidates competing to raise funds for blood cancer research and cures. In its second year, the North...

2014-04-08 08:30:17

Patent provides protection until 2033 and complements Epizyme's issued composition of matter claims for EZH2 inhibitors CAMBRIDGE, Mass., April 8, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,691,507 with claims that cover the identification of patients...

2014-04-02 12:31:39

New Program Brings Busy Moms Together to Get In Shape, Meet Other Moms and Raise Funds to Help Fight Cancer SAN FRANCISCO, April 2, 2014 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society's (LLS) Greater Bay Area Chapter has launched Moms In Training, a brand new nine-week workout program geared towards helping busy moms prepare for a 5K race, while meeting other moms in their community and raising funds for LLS's mission to fight blood cancer. Moms In Training is based...

2014-03-31 12:29:50

WHITE PLAINS, N.Y., March 31, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society today announced that its Canadian affiliate, The Leukemia & Lymphoma Society of Canada (LLSC), has named Shelagh Tippet-Fagyas as its new president, effective today. http://photos.prnewswire.com/prnvar/20140331/NY94346 Tippet-Fagyas will lead LLSC in its efforts to find cures and ensure access to therapies for all blood cancer patients in Canada. She will be working with the LLSC Board of...

2014-03-31 08:29:19

SANTA MONICA, Calif., March 31, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT(TM)) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the Company's lead investigational therapy, an autologous engineered T cell product that targets CD19 expression on B cell malignancies, for...

2014-03-28 08:26:35

MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, March 28, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche's new subcutaneous (SC) formulation of MabThera(®)( )(rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. Following the approval of Herceptin SC in...

2014-03-25 23:31:01

Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too Raleigh, North Carolina (PRWEB) March 25, 2014 Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. These findings have just been posted on the Non-Hodgkin’s Lymphoma Center at...

2014-03-24 20:23:49

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/7dhkqb/investigation) has announced the addition of the "Investigation Report on China Rituximab Market, 2009-2018" [http://www.researchandmarkets.com/research/7dhkqb/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Rituximab (trade names ""MabThera"" by Roche, ""Rituxan"" by Genetech) is a chimeric...